Drug intelligence / Profile preview

Q301

Development stage: Phase 2
Lead developer: Qurient
Modality: Small Molecules
Administration: Topical

Overview

Q301 is a topical formulation of zileuton, a 5-lipoxygenase (5-LO) inhibitor, being developed for the treatment of atopic dermatitis. It is the first topical leukotriene inhibitor for atopic dermatitis, designed to target inflammatory processes by inhibiting the production of leukotrienes, particularly leukotriene B4 (LTB4), which plays a significant role in atopic dermatitis progression by recruiting inflammatory cells to the lesion. The topical formulation aims to maximize pharmaceutical effects while minimizing systemic absorption and potential toxicity.

Other names: topical zileuton

Targets

ALOX12 (Arachidonate 12-lipoxygenase, 12S type)

Beyond the preview

Go deeper on Q301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Q301.

Explore the full profile